JP Morgan Sets $75 Price Target for Enliven Therapeutics
JP Morgan has initiated coverage on Enliven Therapeutics with an Overweight rating and a price target of $75.00 per share.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.